BUILDING BRIDGES IN PEDIATRIC HEMATOLOGY-ONCOLOGY

In memoriam of Marianna V. Vardinoyannis, Founder of ELPIDA Association

Sponsored by

ΕΛΠΙΔΑ
ΣΥΛΛΟΓΟΣ ΦΙΛΩΝ ΠΑΙΔΙΩΝ ΜΕ ΚΑΡΚΙΝΟ
ELPIDA
ASSOCIATION OF FRIENDS OF CHILDREN WITH CANCER

An Educational Hybrid Conference organized by:
Hellenic Society of Pediatric Hematology-Oncology
in collaboration with

- ELPIDA – Marianna V. Vardinoyannis Children's Oncology Unit
- Children's Hospital of Philadelphia
- Princess Máxima Center for Pediatric Oncology, Utrecht
- Hopp Children's Cancer Center Heidelberg (KiTZ)
German Cancer Center (DKFZ)
- The Hospital for Sick Children (SickKids), Toronto



The event will be awarded with 13 ECMECs

PROGRAMME

19 & 20 APRIL 2024

NJV ATHENS PLAZA

Organized by

Hellenic Society of Pediatric Hematology - Oncology

European Reference Network
for rare or low prevalence complex diseases

Under the auspices of

MINISTRY OF HEALTH AND SOCIAL SOLIDARITY



GREETINGS

BUILDING BRIDGES IN PEDIATRIC HEMATOLOGY-ONCOLOGY

In memoriam of
Marianna V. Vardinoyannis,
Founder of ELPIDA Association

ΕΛΠΙΔΑ
ΣΥΛΛΟΓΟΣ ΦΙΛΩΝ ΠΑΙΔΙΩΝ ΜΕ ΚΑΡΚΙΝΟ
ELPIDA
ASSOCIATION OF FRIENDS OF CHILDREN WITH CANCER

Christianna V. Vardinoyannis

Dear guests,

Dear friends and supporters of «ELPIDA Association of Friends of children with cancer»,
It is such a great honor for all of us in the «ELPIDA Association of Friends of Children with cancer» to welcome you to Athens for the Educational Hybrid Conference «Building Bridges in Pediatric Hematology – Oncology», a scientific initiative that brings together the most prominent doctors and scientists from different countries to discuss about childhood cancer, building a bridge of global hope and cooperation for the children of the world.
ELPIDA Association has been fighting against childhood cancer for almost 35 years, since its founding in 1990 by our late Founder Marianna V. Vardinoyannis. Thanks to the tremendous scientific progress of the last decades, in which all of you have greatly contributed, the future for the children suffering from cancer looks much brighter now.

Marianna V. Vardinoyannis had always had a vision to create a world without borders for the health of children, and thanks to her commitment to this goal, "ELPIDA Association" and the "Marianna V. Vardinoyannis-ELPIDA Oncology Unit" have established synergies and cooperations with major Hospitals, Institutions and scientists around the world, some of which are participating in this Conference.

This is why I cannot imagine of a more appropriate and touching tribute in Marianna's memory than this Conference, that brings together, in her home country, some of the most important doctors, scientists and researchers giving them the opportunity to form a strong alliance for the benefit of our little heroes.
"Even the life of just one child is worth the fight". That was Marianna's moto. I strongly believe that thanks to your dedication to scientific progress, thanks to your hard work and continuous efforts, all of us -united- can change the lives of not just one, but of thousands of children with cancer!
From the bottom of my heart, I would like to thank each and every one of you for your participation.
Special thanks to the Hellenic Society of Pediatric Hematology Oncology, and its President Dr. Sophia Polychronopoulou, and also to Professor Antonis Kattamis and Doctors Dimitrios Doganis, Evgenios Gousetis and Vasilios Papadakis for the fruitful cooperation organizing this Conference.
Best of success for this unique joint effort for the children of the world.

Christianna V. Vardinoyannis
President of ELPIDA Association of Friends of Children with cancer

Polychronopoulou Sophia

Greeting of the President of Hellenic Society of Paediatric Haematology and Oncology (HeSPHO) at the Conference "BUILDING BRIDGES IN PEDIATRIC HEMATOLOGY – ONCOLOGY 2024"

I am delighted to be given the opportunity to address **the Educational Hybrid Conference entitled "BUILDING BRIDGES IN PEDIATRIC HEMATOLOGY – ONCOLOGY 2024"**.

This Conference is one of the many important educational activities, sponsored by the "ELPIDA" Foundation and honourably continues the vision of its inspirer and founder, **Mrs. Marianna V. Vardinoyannis, in memoriam of whom this scientific event is dedicated**.

ELPIDA Association tirelessly continues to serve its vision and work for the creation of a map of peace and hope among peoples, with health as a means to achieve this.

Marianna V. Vardinoyannis' efforts against childhood cancer have been long standing and expanding over 30 years. She undertook a great number of initiatives that aimed at helping sick children with cancer and their families. Through her personal meticulous work and through the "ELPIDA" Association of Friends of Children with Cancer, she founded the first Paediatric Bone Marrow Transplantation Unit in Greece, the ELPIDA Pediatric Oncology Unit and the first Hellenic Bone Marrow Volunteer Donor Bank, all affiliated and located at the AGHIA SOPHIA CHILDREN'S HOSPITAL, and last but not least, the "ELPIDA" Guest House for the families of children with cancer.

This conference is of great importance as it promotes and supports the international cooperation of Greek Pediatric Hematologists-Oncologists with important colleagues from well known paediatric cancer centers from abroad, and has the ultimate goal to serve as the platform of continuous information and training for health professionals.

I am very pleased to see that the topics covered by the conference are of seminal importance and touch on significant scientific areas in the spectrum of solid tumors, hematologic malignancies and the supportive care of children with cancer, with the aim of sharing up-to-date knowledge within the Hellenic Pediatric Hematology-Oncology community.

BUILDING BRIDGES IN PEDIATRIC HEMATOLOGY-ONCOLOGY

In memoriam of
Marianna V. Vardinoyannis,
Founder of ELPIDA Association

ΕΛΠΙΔΑ
ΣΥΛΛΟΓΟΣ ΦΙΛΩΝ ΠΑΙΔΙΩΝ ΜΕ ΚΑΡΚΙΝΟ
ELPIDA
ASSOCIATION OF FRIENDS OF CHILDREN WITH CANCER

I am sure that during the work of the two-day conference, the participants will be given the opportunity to exchange views on a multitude of issues and thus define a common policy in the field of dealing with childhood cancer.

The Hellenic Society of Pediatric Hematology-Oncology (HeSPHO/EEPAO), representing more than 300 Health professionals working with Paediatric and Adolescent Cancer, from all over Greece, welcomes and is always keen to support such important scientific events. In an era of rapid scientific development across the board of Pediatric Hematology Oncology, with new technologies and breakthrough methods at our doorstep ready to make a true revolution in medical science, events such as this of today, benefit our growing community of experts and provide health professionals the opportunity to educate themselves in these new treatments, upgrading our health services and approach for our children and adolescents with cancer.

Looking forward to what it promises to be a great two-day scientific event, I wish to congratulate the organizing and scientific committee, for their dedication with which they worked to make this Conference open scientific and development platform to all participants.

I would like, on behalf of HeSPHO, to welcome the distinguished presenters from both Greece and abroad who have worked diligently for the success of this Conference. I am sure that in addition to the scientific updates, this two-day conference is a means of getting to know each other, developing local and international friendships and cooperations that will last for the years to come.

I take today's opportunity to assure you that the Hellenic Society of Pediatric Hematology-Oncology (HeSPHO), stands by you and supports your efforts in every way we can.
I wish every success in the works of the Conference !!

Sophia Polychronopoulou
MD, PhD, Paediatrician and Hematologist,
President of the Hellenic Society of Paediatric Haematology and Oncology (HeSPHO)

Kattamis Antonis

Dear Colleagues,
Dear Friends,

We would like to invite you to our International Conference on Pediatric Hematology and Oncology which will be held in Athens on April 19–20, 2024.
The conference is held every two years in collaboration with the colleagues of the Children's Hospital of Philadelphia. This year, our Conference is organized by the Departments of the Oncology Center 'ELPIDA-Marianna V. Vardinoyannis' with the participation of esteemed and well-known faculty from Europe and North America.

The title of the conference is '**Building Bridges on Pediatric Hematology-Oncology**', as we would like to emphasize the importance of international collaboration for improving the best and updated treatments for our patients.

Metaphorically, our 'bridges' imply the pathway towards hope and cure.

The Conference is dedicated to the memory of Mrs. Marianna V. Vardinoyannis, the founder and driving power of the 'ELPIDA – Association of Friends of Children with Cancer', that developed that idea and coordinated the building of the Oncology Center. The Conference has been financially supported solely by the 'ELPIDA-Association'.

We hope to welcome you in Athens for a great program and scientific interaction.

The Scientific Committee,

BUILDING BRIDGES IN PEDIATRIC HEMATOLOGY-ONCOLOGY

In memoriam of
Marianna V. Vardinoyannis,
Founder of ELPIDA Association

ΕΛΠΙΔΑ
ΣΥΛΛΟΓΟΣ ΦΙΛΩΝ ΠΑΙΔΙΩΝ ΜΕ ΚΑΡΚΙΝΟ
ELPIDA
ASSOCIATION OF FRIENDS OF CHILDREN WITH CANCER

DAY ONE | FRIDAY **19 APRIL** 2024 | **NJV** ATHENS PLAZA

		INSTITUTION	SPEAKER
9:15 – 9:30	WELCOME AND INTRODUCTION		
9:30 – 11:00	**CHAIRS** Dimitris Doganis Marry van den Heuvel-Eibrink		
SOLID TUMORS-1	WILMS: Introduction Bridging SIOP and COG	ELPIDA – MARIANNA V. VARDINOYANNIS CHILDREN'S ONCOLOGY UNIT	Dimitris Doganis
	WILMS, the SIOP-RTSG approach, progress through international collaboration	PRINCESS MÁXIMA CENTER FOR PEDIATRIC ONCOLOGY	Marry van den Heuvel-Eibrink
	WILMS – COG approach	CHILDREN'S HOSPITAL OF PHILADELPHIA	Nicholas Evageliou
	Genetic predisposition for WILMS	ELPIDA – MARIANNA V. VARDINOYANNIS CHILDREN'S ONCOLOGY UNIT	Periklis Makrythanasis
11:00 – 11:30	COFFEE BREAK		
11:30 – 13:00	**CHAIRS** Vassilios Papadakis Rochelle Bagatell		
SOLID TUMORS-2	Rethinking High-Risk Neuroblastoma Therapy in the Frontline Setting: A North American Perspective	CHILDREN'S HOSPITAL OF PHILADELPHIA	Rochelle Bagatell
	Neuroblastoma – Novel Approaches / developments (SIOPEN)	ELPIDA – MARIANNA V. VARDINOYANNIS CHILDREN'S ONCOLOGY UNIT	Vassilios Papadakis
	Current and future strategies for relapse / refractory high-risk neuroblastoma	SICKKIDS	Daniel Morgenstern
13:00 – 14:30	LUNCH BREAK		

DAY ONE | FRIDAY 19 APRIL 2024 | NJV ATHENS PLAZA

		INSTITUTION	SPEAKER
14:30 – 16:30	**CHAIRS** Antonis Kattamis Olaf Witt		
CNS Tumors	Low grade gliomas: how I treat (NF and non-NF)	CHILDREN'S HOSPITAL OF PHILADELPHIA	Cassie Kline
	GENTURIS guidelines for NF: "gnous pratte"	ELPIDA – MARIANNA V. VARDINOYANNIS CHILDREN'S ONCOLOGY UNIT	Kleoniki Roka
Advances in diagnosis and treatment	Pediatric Precision Oncology in INFORM: lessons learned and future developments	DKFZ GERMAN CANCER RESEARCH CENTER	Olaf Witt
	Participation in the INFORM study: The Greek Contribution	ELPIDA – MARIANNA V. VARDINOYANNIS CHILDREN'S ONCOLOGY UNIT	Maria Filippidou
	Drug Development in Pediatric Oncology	PRINCESS MÁXIMA CENTER FOR PEDIATRIC ONCOLOGY	Michel Zwaan
16:30 – 17:00	COFFEE BREAK		
17:00 – 18:30	**CHAIRS** Zenia Saridaki Eftichia Stiakaki Theodora Psaltopoulou		
AYA	Translational genomics and targeted therapy of Ewing sarcoma	DKFZ GERMAN CANCER RESEARCH CENTER	Thomas Grünewald
	Special needs of the adolescent patient	UNIVERSITY OF THESSALY	Emmanouil Saloustros
	Treating AYA patients: exchange of experiences	CHOP – DKFZ – PMC GREECE	Discussion
19:30 – 22:30	OPENING CEREMONY-RECEPTION		

BUILDING BRIDGES IN PEDIATRIC HEMATOLOGY-ONCOLOGY

In memoriam of
Marianna V. Vardinoyannis,
Founder of ELPIDA Association

ΕΛΠΙΔΑ
ΕΥΑΛΩΤΟΣ ΦΙΛΩΝ ΠΑΙΔΙΩΝ ΜΕ ΚΑΡΚΙΝΟ
ELPIDA
ASSOCIATION OF FRIENDS OF CHILDREN WITH CANCER

DAY TWO | SATURDAY **20 APRIL** 2024 | **NJV** ATHENS PLAZA

		INSTITUTION	SPEAKER
9:30 – 11:30	**CHAIRS** Sophia Polychronopoulou Evgenios Gousetis		
ALL	Emerging molecular/cytogenetic markers at diagnosis	ELPIDA – MARIANNA V. VARDINOYANNIS CHILDREN'S ONCOLOGY UNIT	Mirella Ampatzidou
	Emerging molecular/cytogenetic markers at cell therapies	ELPIDA – MARIANNA V. VARDINOYANNIS CHILDREN'S ONCOLOGY UNIT	Christina Oikonomopoulou
	ALL Novel immunotherapies apart CAR-T	CHILDREN'S HOSPITAL OF PHILADELPHIA	Stephen Hunger
	The role of alloBMT in first line ALL treatment	CHILDREN'S HOSPITAL OF PHILADELPHIA	Alix Seif
	Tailored graft strategy for children receiving unrelated peripheral blood stem cell transplantation	ELPIDA – MARIANNA V. VARDINOYANNIS CHILDREN'S ONCOLOGY UNIT	Aikaterini Kaisari
	Donor derived Car-T cells for relapses of pediatric CD19 + B-ALL after HSCT	ELPIDA – MARIANNA V. VARDINOYANNIS CHILDREN'S ONCOLOGY UNIT	Anna Komitopoulou
11:30 – 12:00	COFFEE BREAK		
12:00 – 14:00	**CHAIRS** Maria Pagoni Georgia Avgerinou		
	Infant acute lymphoblastic leukemia – the INTERFANT experience	PRINCESS MÁXIMA CENTER FOR PEDIATRIC ONCOLOGY	Janine Stutterheim
	Emerging therapies for pediatric AML	CHILDREN'S HOSPITAL OF PHILADELPHIA	Sarah Tasian
	The future of CAR-T therapies (all indications)	CHILDREN'S HOSPITAL OF PHILADELPHIA	Steve Grupp

DAY TWO | SATURDAY 20 APRIL 2024 | NJV ATHENS PLAZA

		INSTITUTION	SPEAKER
14:00 – 15:30	LUNCH		
15:30 – 18:00	**CHAIRS** Marina Servitzoglou Charikleia Kelaidi		
SUPPORTIVE CARE	Cancer Predisposition Syndromes – introduction	ELPIDA – MARIANNA V. VARDINOYANNIS CHILDREN'S ONCOLOGY UNIT	Antonis Kattamis
	Cancer Predisposition in Pediatrics: considerations for testing and screening in children	CHILDREN'S HOSPITAL OF PHILADELPHIA	Suzanne MacFarland
	The success story of volunteer haematopoietic stem cell donation in Greece. The role of ORAMA ELPIDAS Bone Marrow Donor Center	ELPIDA – MARIANNA V. VARDINOYANNIS CHILDREN'S ONCOLOGY UNIT	Sophia Karatasaki
	ID Prophylaxis in pediatric Oncology	ELPIDA / CHILDREN'S HOSPITAL OF PHILADELPHIA	Theoklis Zaoutis
	Paving the way for probiotic therapy in childhood cancer	ELPIDA UNIVERSITY OF COLUMBIA	Elena Ladas
	Psychosocial care for children and adolescents with cancer	ELPIDA – MARIANNA V. VARDINOYANNIS CHILDREN'S ONCOLOGY UNIT	Marina Servitzoglou
	Psychological care after the end of therapy	ELPIDA ASSOCIATION	Dimitrios Nanis



TITLES
OF SPEAKER & CHAIRS

BUILDING BRIDGES IN PEDIATRIC HEMATOLOGY-ONCOLOGY

In memoriam of
Marianna V. Vardinoyannis,
Founder of ELPIDA Association

ΕΛΠΙΔΑ
ΕΥΛΑΞΟΣ ΦΙΛΩΝ ΠΑΙΔΙΩΝ ΜΕ ΚΑΡΚΙΝΟ
ELPIDA
ASSOCIATION OF FRIENDS OF CHILDREN WITH CANCER

TITLES OF SPEAKER & CHAIRS

NAME	TITLE
AMPATZIDOU MIRELLA	MD, PhD, Hematologist, Senior Consultant Department of Pediatric Hematology Oncology (T.A.O.) "Aghia Sophia" Children's Hospital, Athens, Greece
AVGERINOU GEORGIA	MD, PhD, Hematologist, Division of Pediatric Hematology – Oncology, First Department of Pediatrics, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Athens, Greece
BAGATELL ROCHELLE (RO)	MD, Solid Tumor Section Chief, Children's Hospital of Philadelphia Professor of Pediatrics, Perelman School of Medicine, University of Pennsylvania
DOGANIS DIMITRIS	MD, PhD, MSc, Pediatric Oncologist, Head – NHS Director of Oncology Department of P&A Kyriakou Children's Hospital (OTAK), Children's Oncology Unit "Marianna V. Vardinoyannis-ELPIDA", Athens, Greece
EVAGELIOU NICHOLAS (NICK)	MD, Medical Director, Hematology/Oncology Clinic, Specialty Care & Surgery Center, Voorhees, NJ Associate Professor of Clinical Pediatrics in Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania
FILIPPIDOU MARIA	Attending Physician, Division of Pediatric Hematology-Oncology First Department of Pediatrics, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Athens, Greece, Guest-scientist, German Cancer Research Center (DKFZ), Hopp Children's Cancer Center (KiTZ), University of Heidelberg, Germany
GOUSETIS EVGENIOS	Pediatric Hematologist – Oncologist, Director of STEM Cell Transplant and Cellular Therapies Unit, Children's Oncology Unit "Marianna V. Vardinoyannis – ELPIDA", "Aghia Sophia" Children's Hospital, Athens, Greece
GRUNEWALD THOMAS	MD, PhD, Division of Translational Pediatric Sarcoma Research (B410), Hopp Children`s Cancer Center Heidelberg (KiTZ) and German Cancer Research Center (DKFZ)

TITLES OF SPEAKER & CHAIRS

NAME	TITLE
GRUPP STEFAN (STEVE)	MD, PhD, Chief, Cellular Therapy and Transplant Section, Children's Hospital of Philadelphia Director, Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy, Children's Hospital of Philadelphia Medical Director, Cell and Gene Therapy Laboratory, Children's Hospital of Philadelphia Co-Lead, Pediatric Oncology, Abramson Cancer Center Yetta Deitch Novotny Endowed Chair in Pediatric Oncology, Children's Hospital of Philadelphia Novotny Professor of Pediatrics, Perelman School of Medicine, University of Pennsylvania
HUNGER STEPHEN (STEVE)	MD, Chief, Division of Pediatric Oncology, Director, Center for Childhood Cancer Research, Associate Director (Pediatric Cancer Research), Abramson Cancer Center Jeffrey E. Perelman Distinguished Chair in the Department of Pediatrics, Children's Hospital of Philadelphia Professor of Pediatrics, Perelman School of Medicine, University of Pennsylvania
KAISARI AIKATERINI	Hematologist, BMT Unit, Children's Oncology Unit "Marianna V. Vardinoyannis -ELPIDA", "Aghia Sophia" Children's Hospital, Athens, Greece
KARATASAKI SOFIA	Mphil, Search & Transplant Coordinator
KATTAMIS ANTONIS	Professor of Pediatric Hematology/Oncology Head, Division of Pediatric Hematology/Oncology, First Department of Pediatrics – National & Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Athens, Greece
KELAIDI CHARIKLEIA	Hematologist, NHS Director, Department of Pediatric Hematology Oncology (T.A.O.), "Aghia Sophia" Children's Hospital, Athens, Greece
KLINE CASSIE	MD, MAS, Attending Physician Director, Neuro-Oncology Clinical Research Division of Oncology, The Children's Hospital of Philadelphia Project Co-Leader and Director of Data Quality and Integration, Pediatric Neuro-Oncology Consortium
KOMITOPOULOU ANNA	Haematologist, MD, PhD, ELPIDA Stem Cell Transplant Unit-Centre for Cell and Gene Therapy, Children's Oncology Unit "Marianna V. Vardinoyannis – ELPIDA" "Aghia Sophia" Children's Hospital, Athens, Greece

BUILDING BRIDGES IN PEDIATRIC HEMATOLOGY-ONCOLOGY

In memoriam of
Marianna V. Vardinoyannis,
Founder of ELPIDA Association

ΕΛΠΙΔΑ
ΕΥΛΑΞΟΣ ΦΙΛΩΝ ΠΑΙΔΙΩΝ ΜΕ ΚΑΡΚΙΝΟ
ELPIDA
ASSOCIATION OF FRIENDS OF CHILDREN WITH CANCER

TITLES OF SPEAKER & CHAIRS

NAME	TITLE
LADA ELENA	PhD, RD, Sid and Helaine Lerner Professor for Global Integrative Medicine, Columbia University Irving Medical Center, Co-Director, Center for Comprehensive Wellness Director, International Initiative for Pediatrics and Nutrition Associate Research Director, Pediatric Obesity Program
MACFARLAND SUZANNE	MD, MS, Assistant Professor of Pediatrics (Oncology), Perelman School of Medicine, University of Pennsylvania
MAKRYTHANASIS PERIKLIS	MD, PhD, PD, Asst Professor Medical Genetics Laboratory of Medical Genetics | Medical School | National and Kapodistrian University of Athens
MORGENSTERN DANIEL	MB BChir PhD Staff Oncologist Hospital for Sick Children Toronto Associate Professor Department of Paediatrics, University of Toronto
NANIS DIMITRIOS	Social Worker, PHD Candidate Head of Psychosocial Support Services Guesthouse ELPIDA
OIKONOMOPOULOU CHRISTINA	Hematologist, Senior Consultant, BMT Unit "Aghia Sophia" Children's Hospital, Athens, Greece
PAGONI MARIA	Hematologist, Senior Consultant, Hematology Dept. and BMT Unit Evangelismos General Hospital
PAPADAKIS VASSILIOS	MD PhD, Pediatric Hematologist- Oncologist Head of the Department of Pediatric Hematology- Oncology (TAO), Oncology Unit Marianna V Vardinoyannis- ELPIDA "Agia Sofia" Children's Hospital, Athens, Greece National Coordinator for Neuroblastoma and Histiocytoses
POLYCHRONOPOULOU SOPHIA	MD, PhD, President of the Hellenic Society of Paediatric Haematology Oncology (HeSPHO)
PSALTOPOULOU THEODORA	Professor of Epidemiology and Preventive Medicine, Medical School National and Kapodistrian University of Athens

TITLES OF SPEAKER & CHAIRS

NAME	TITLE
ROKA KLEONIKI	Paediatrician, MD, PhD, Senior Attending Physician Division of Pediatric Hematology-Oncology, First Department of Pediatrics, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Greece
SALOUSTROS EMMANOUIL	Assoc. Professor of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly
SARIDAKI – ZORAS ZENIA	MD PhD, Medical Oncologist, President of the BoD of the Hellenic Society of Medical Oncology (HeSMO), Director at the 1st Oncology Dept. Metropolitan Hospital, Athens Scientific Director of the Oncology Department "Asklepios DIAGNOSIS", Heraklion Crete
SEIF ALIX	MD, MPH, Richard and Sheila Sanford Endowed Chair in Pediatric Oncology, Children's Hospital of Philadelphia Associate Director of Clinical Research, Center for Childhood Cancer Research, Children's Hospital of Philadelphia Innovation Faculty, Penn Center for Cancer Care Innovation (PC3I) Associate Professor, Perelman School of Medicine, University of Pennsylvania
SERVITZOGLOU MARINA	Pediatric Oncologist, NHS Consultant Children's Hospital "P. & A. Kyriakou"
STIAKAKI EFTICHIA	Professor of Pediatric Hematology-Oncology, Medical School University of Crete, Head of the Department Pediatric Hematology-Oncology University Hospital of Heraklion, Greece
STUTTERHEIM JANINE	MD, PhD, Pediatric oncologist, department hemato-oncology Princess Maxima center for pediatric oncology
TASIAN SARAH	MD, Chief, Hematologic Malignancies Program, Children's Hospital of Philadelphia Joshua Kahan Endowed Chair in Pediatric Leukemia, Children's Hospital of Philadelphia Associate Professor of Pediatrics, Perelman School of Medicine, University of Pennsylvania

BUILDING BRIDGES IN PEDIATRIC HEMATOLOGY-ONCOLOGY

In memoriam of
Marianna V. Vardinoyannis,
Founder of ELPIDA Association

ΕΛΠΙΔΑ
ΕΥΑΛΟΓΟΣ ΦΙΛΩΝ ΠΑΙΔΙΩΝ ΜΕ ΚΑΡΚΙΝΟ
ELPIDA
ASSOCIATION OF FRIENDS OF CHILDREN WITH CANCER

TITLES OF SPEAKER & CHAIRS

NAME	TITLE
VAN DEN HEUVEL – EIBRINK MARRY	Prof. Dr. University of Utrecht, Pediatric Oncologist, and Principal Investigator, Princess Máxima Center for Pediatric Oncology Chair SIOP-RTSG and Coordinator SIOP-RTSG office
WITT OLAF	Prof. Dr. med. KiTZ Director translational Program Head of the division Clinical Cooperation Unit Pediatric Oncology, DKFZ; head of KiTZ Clinical Trial Unit (ZIPO) and Brain Tumors Deputy Chief of the Department of Pediatric Oncology, Hematology Immunology and Pulmonology, Heidelberg University Hospital
ZAOUTIS THEOKLIS	MD, MSCE, PhD, Professor of Pediatrics, 2nd Department of Pediatrics, National and Kapodistrian University of Athens, Greece, Emeritus Professor of Pediatrics, University of Pennsylvania, and The Children's Hospital of Philadelphia
ZWAAN MICHEL	Prof. Dr. Pediatric Oncologist And Head Trial and Data Center

SPEECH TOPIC

SHORT BIO

BUILDING BRIDGES IN PEDIATRIC HEMATOLOGY-ONCOLOGY

In memoriam of
Marianna V. Vardinoyannis,
Founder of ELPIDA Association

ΕΛΠΙΔΑ
ΣΥΛΛΟΓΟΣ ΦΙΛΩΝ ΠΑΙΔΙΩΝ ΜΕ ΚΑΡΚΙΝΟ
ELPIDA
ASSOCIATION OF FRIENDS OF CHILDREN WITH CANCER

SPEECH TOPIC & SHORT BIO

Ampatzidou Mirella | Hematologist, MD, PhD

Emerging molecular/cytogenetic markers at diagnosis of Acute Lymphoblastic Leukemia (ALL)

During the past decades, the evolvement of genome-wide technologies and the identification of recurrent chromosomal abnormalities and gene copy-number alterations (CNAs) implicated in leukemogenesis have led to a constant decoding of the underlying biology of pediatric ALL. Thus, major survival improvements have been accomplished through the refinement of the risk-adapted approach and MRD-guided treatment, as well as due to the enhanced delineation of the underlying disease biology. Apart from the well-established favorable or adverse genetic aberrations, modern therapeutic protocols are currently incorporating the combined evaluation of the copy-number status of selected genes (CNA-classifiers), which may also serve as adverse modifiers. Additionally, emerging new recurrent chromosomal abnormalities, aberration-like entities, CNAs and lately described new genomic features and variants within heterogenous subgroups, represent novel proposed factors for predicting relapse and survival. Emerging distinct genetic entities are herein addressed and described, that may serve as novel genomic features incorporated into future risk-stratification algorithms, in an effort to further genetically refine MRD-based stratification and improve treatment-group allocation and ultimate patient outcome.

CV

Senior Consultant NHS, Department of Pediatric Hematology-Oncology (TAO) of "Aghia Sophia" Children's Hospital, ELPIDA-Marianna V. Vardinoyannis Children's Oncology Unit

- Special interest in the fields of Acute Lymphoblastic Leukemia (ALL), relapsed ALL, Biology and Diagnostics, Chronic Myeloid Leukemia (CML)
- Member of the iBFM Committees of Biology and Diagnostics (B&D), ALL, ResDis, Genetic Variation (GV) and CML
- Member of the ALL IC BFM 2022 Steering and Writing Committee
- Member of the ALL IC Relapse 2022 Writing and Scientific Committee
- HeSPHO-CML-WG National Coordinator
- Interfant-21 HeSPHO National PI
- SIOPE/ERN Ped Can ALL European Standard Clinical Practice Guidelines (ALL-ESCP) Writing Committee
- Member of the HTA National Committee

SPEECH TOPIC & SHORT BIO

Bagatell Rochelle | MD

Rethinking High-Risk Neuroblastoma Therapy in the Frontline Setting:
A North American Perspective
(Solid Tumors – 2)

Current therapy for children with newly diagnosed high-risk neuroblastoma is very intensive and makes use of multiple treatment modalities. However, survival rates for this patient population remain poor. As new agents for neuroblastoma are developed, we have the opportunity to re-think the components of standard high-risk therapy. In addition, as new tools to predict and assess response to therapy are also developed, there may be important opportunities to alter treatment and improve survival.

CV

Personal Statement:

My research is focused on improving therapies for children with neuroblastoma. I lead clinical research designed to critically evaluate current therapies for children with high-risk and relapsed disease, and I am committed to conducting studies of new therapies for this population. My role as Chair of the Children's Oncology Group Neuroblastoma Committee and my position as Solid Tumor Section Chief at The Children's Hospital of Philadelphia have given me a deep understanding of the challenges facing patients and families at the time of diagnosis and throughout therapy. I have a strong track record in clinical research and have experience partnering with laboratory-based colleagues to address important questions in the field.

Doganis Dimitris

WILMS: Introduction
Bridging SIOP and COG
(Solid Tumors – 1)

Wilms tumor (WT) is one of the great success stories in pediatric oncology with survival rates more than 90%. Nevertheless, survival remains low for a group of patients (bilateral disease, unfavourable histological-molecular features, relapses) which accounts for about 25% of patients. Consequently, there is need for new treatment agents & approaches. Moreover, the «cost of treatment» (cardiotoxicity, second malignancies, fertility, renal dysfunction) should be taken into consideration.
There are two main approaches regarding the management of WT patients (SIOP-RTSG and COG) with differences regarding the time point of tumor removal and risk stratification but with similar outcomes. Both groups need additional clinical and biological prognostic markers for better risk stratification and risk-adapted treatment. These markers should be tested in patients exposed to different treatment approaches. Given the small numbers also, there is need for international collaboration between the major groups which already share ideas, data, criteria with a common aim: the best care for all children with WT.
Hellenic Society of Pediatrc Hematology-Oncology Renal Tumor Study Group (HeSPHO-RTSG) participates as country – among the first five – in Umbrella Study. «Learning from the Experts and Building Bridges in Pediatric Hematology – Oncology» are the main aims of this meeting and our HeSPHO-RTSG group.

CV

Dimitrios Doganis, MD, PhD, MSc, is Pediatric Oncologist, Head – NHS Director of Oncology Department of «P&A Kyriakou» Children's Hospital, Children's Oncology Unit «Marianna V. Vardinoyannis-ELPIDA», Athens, Greece. He graduated from the Medical School – «National & Kapodistrian University of Athens» and awarded specialty in Pediatrics in «P&A Kyriakou» Children's Hospital. He further specialized in Pediatric Hematology-Oncology in «P&A Kyriakou» Children's Hospital, Oncology Dpt and in Children's Hospital of Michigan, Wayne State University, Detroit, USA, Hematology-Oncology Dpt, where his research activities involved, additionally, «Infections in Children with Cancer», with relevant cited publications. He received his PhD from the Medical School of Athens – National & Kapodistrian University of Athens whereas a Health Care Administration Master Degree (Magister Artium) has also been obtained (Thesis: Prognostic factors for Blood Stream Infections in Children with Cancer) from the Open University of Cyprus (School of Financial Sciences and Administration).
He was appointed at the Oncology Department of «P&A Kyriakou Children's Hospital (OTAK), in 2002, where he is still working, at the Head of Department position level. Current practice and research interest involve all fields of Pediatric Oncology. He is a member of Renal Tumor Study Group of the International Society of Paediatric Oncology (SIOP-RTSG) and he is the National coordinator of the Hellenic Society of Pediatric Hematology

SPEECH TOPIC & SHORT BIO

Oncology (HeSPHO) – Renal Tumor Study Group of SIOP-RTSG and the Principal Investigator in Greece for the current Trial Umbrella for Childhood Renal Tumors within SIOP. He is the main author of several publications regarding renal tumors in childhood and author / co-author of numerous scientific papers in all fields of Pediatric Oncology as well. Among them, several research studies have been awarded. He has also been awarded several scholarships during his training / work. In his research activities, many cooperative studies, at national and international level, are included whereas numerous phase I-III research projects have been conducted by him at OTAK, in most of them as local PI. He is reviewer in several local and international medical journals and a member in many national and international scientific societies being also the Secretary General of HeSPHO.

Evageliou Nicholas | MD

WILMS – COG approach
(Solid Tumors – 1)

Wilms Tumor outcomes are excellent overall. This presents the unique challenge of how to improve future care for our patients. The way to improve is through improved risk stratification, which ultimately allows for deintensification of therapy for favorable risk groups (and consequent decrease in late effects) while intensifying therapy for subgroups of patients with poor outcomes, such as anaplasia. This talk will provide an overview of past results and future efforts to improve outcomes, from the perspective of the Children's Oncology Group (COG) Renal Tumor Committee. Finally, a brief discussion of ways to harmonize efforts between COG and SIOP will be addressed.

CV

Personal Statement:

I am a CHOP clinician with a broad practice in hematology and oncology. My past basic science research focused on neuroblastoma and the effect of manipulating polyamines for treatment of this childhood tumor. Currently my research interest is in the area of kidney tumors, and I am active with the Children's Oncology Group Renal Tumor Committee where my work focuses on clinical trials for favorable histology Wilms tumors. I am currently vice-chair on two renal tumors' protocols through this group.

Filippidou Maria

Participation in the INFORM study:
The Greek Contribution
(Advances in diagnosis and treatment)

The INFORM (INdividualized Therapy FOr Relapsed Malignancies in Childhood) Study is the prime example of a personalized oncology program for pediatric patients in Europe. The concept of the INFORM-Study is to biologically characterize tumor samples for all pediatric patients with high-risk disease for which no further standard of care therapy is available, independently of histological diagnosis. Since 2018, 110 eligible patients from Greece have been enrolled in the INFORM Study. Their samples were sent to Heidelberg for thorough molecular analysis to identify potentially actionable molecular targets for experimental therapies and all results have been discussed in INFORM multidisciplinary tumor boards. In this presentation we will focus on the benefits gained through our country's participation in the Study.

CV

Maria Filippidou is an attending physician at the Pediatric Hematology and Oncology Unit of the First Department of Pediatrics, National and Kapodistrian University of Athens at Aghia Sophia Children's Hospital (Head, Prof. Dr. Antonis Kattamis). She has worked as a researcher at the Division of Pediatric Neuro-oncology at the German Cancer Research Center, DKFZ (Prof. Dr. Stefan M. Pfister) and as an attending physician at the KiTZ Clinical Trial Unit in the Department of Pediatric Oncology, Hematology, and Immunology at the Heidelberg University Hospital. She is a guest scientist at DKFZ, and her main field of interest is pediatric neuro-oncology.

Grünewald Thomas

Translational genomics and targeted therapy of Ewing sarcoma
(AYA)

Many highly aggressive pediatric sarcomas, such as Ewing sarcoma, are driven by and addicted to pathognomonic gene fusions. These gene fusions typically give rise to aberrant oncogenic transcription factors (OTFs) that are equipped with neomorphic DNA-binding capabilities. Due to their tumor-exclusive expression, researchers have attempted to specifically target and suppress the activity of these OTFs, which has – as yet – not led to effective and clinically applicable treatment options. In contrast, we aim at leveraging the unique DNA-binding preferences of OTFs to drive the expression of therapeutic genes specifically in cancer cells. An outline of this innovative approach will be presented.

SPEECH TOPIC & SHORT BIO

CV

Thomas Grünewald serves as Principal Investigator at the German Cancer Research Center (DKFZ) and Hopp-Children's Cancer Center (KiTZ), Professor of Translational Pediatric Sarcoma Research and senior pathologist at the Heidelberg University Hospital (UKHD). His research takes a functional genomics approach to decipher disease mechanisms and to uncover new diagnostic and therapeutic approaches for children, adolescents, and young adults affected by sarcomas. Before coming to Heidelberg, he was a PhD student at the Department of Pediatrics of the Technical University of Munich (TUM), postdoc at the Institut Curie Research Center, Paris, and Max-Eder Junior Research Group Leader at the LMU Munich.

Grupp Stephan | MD, PhD

The future of CAR-T therapies (all indications)

The remarkable success observed in early-phase clinical studies with CD19-targeted CAR T-cells for treating hematologic malignancies has generated significant interest in CAR T cell-based therapies. Currently, there is a growing focus on targeting different types of tumors by incorporating additional tumor-associated antigens such as PSMA, mesothelin, GD2, HER2, and epidermal growth factor receptors. Numerous clinical trials involving CAR T-cells in hematological malignancies are already underway, exploring thousands of combinations of therapies in this area. However, one challenge lies in finding more effective targets for CAR T-cell therapy and identifying suitable combination therapies.

CV

Personal Statement:

I am the Section Chief of the Cellular Therapy and Transplant Section; the Inaugural Director of the Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy; and Medical Director of the Cell and Gene Therapy Laboratory at Children's Hospital of Philadelphia. I hold the Yetta Deitch Novotny Endowed Chair in Pediatric Oncology. In my lab, the research is devoted to developing cell-based and molecularly-targeted therapies to treat leukemia and solid tumors. We develop and conduct preclinical testing of engineered cell therapies and signal transduction inhibitors in leukemia, in pediatric immunotherapy trials, and in the manufacture and use of cellular therapeutics in preclinical, good manufacturing practices, and clinical trial settings. My colleagues and I are global leaders in highly active CAR T cell therapy (CTL019 (CD19 CAR) clinical trials. The goal of all the work I do is to improve treatment options for children with cancer, not just at CHOP but throughout the world.

BUILDING BRIDGES IN PEDIATRIC HEMATOLOGY-ONCOLOGY

In memoriam of
Marianna V. Vardinoyannis,
Founder of ELPIDA Association

ΕΛΠΙΔΑ
ΣΥΛΛΟΓΟΣ ΦΙΛΩΝ ΠΑΙΔΙΩΝ ΜΕ ΚΑΡΚΙΝΟ
ELPIDA
ASSOCIATION OF FRIENDS OF CHILDREN WITH CANCER

SPEECH TOPIC & SHORT BIO

Hunger Stephen | MD

ALL Novel immunotherapies apart CAR-T (ALL)

Data regarding blinatumomab and inotuzumab in pediatric ALL will be discussed. Some of the main issues in moving from single agent therapy to incorporating these agents in regimens for newly diagnosed ALL, including subcutaneous blinatumomab and combining inotuzumab with cytotoxic chemotherapy will be discussed. New immunotherapies in the pipeline will also be addressed.

CV

Personal Statement:

I have been Chief of the Division of Oncology, Director of the Center for Childhood Cancer Research and the Jeffrey E. Perelman Distinguished Chair in the Department of Pediatrics, Children's Hospital of Philadelphia, and a Professor of Pediatrics at the University of Pennsylvania School of Medicine since 2014.
I was educated and trained at the Massachusetts Institute of Technology (BS, 1981), the University of Connecticut Medical School (MD, 1985), Johns Hopkins Hospital (Pediatrics, 1985–88), and Stanford University (Pediatric Hematology/Oncology, 1988–91). I have been a leader in academic medicine for over 20 years as Chief of the University of Florida Pediatric Hematology/Oncology Division (2001–07), Chief of the University of Colorado Pediatric Hematology/Oncology/BMT Division (2007–14)
My specialties are in basic, translational, and clinical research for childhood ALL. I was the Vice-Chair (2001-07) and Chair (2008–2015) of the Children's Oncology Group (COG) ALL Disease Committee and led the COG/NCI High Risk ALL TARGET Project since 2006. This project has made numerous discoveries on the genomic landscape of childhood ALL that have resulted in precision medicine clinical trials in genetically-defined ALL subsets. I have over 375 publications, almost all on childhood ALL, and an h-index of 75 (i10-index 115).

SPEECH TOPIC & SHORT BIO

Kaisari Katerina

Tailored graft strategy for children receiving unrelated peripheral blood stem cell transplantation (ALL)

Transplantation of adults and children with peripheral blood stem cells (PBSCs) is associated with increased incidence of chronic Graft versus Host Disease (cGvHD). The number of CD3+lymphocytes in PBSC grafts is five to ten –fold higher, compared to bone marrow. The role of CD3+ on the incidence of cGvHD is not clear. In our study we processed PBSC grafts from unrelated donors in order to decrease CD3+ lymphocytes at a number comparable to bone marrow grafts. Graft manipulation was done with positive selection of CD34+ cells (CLINIMACS) and then addition of a certain number of CD3+lymphocytes (5 × 107/kgr). The outcome of patients who received these manipulated grafts was compared with the outcome of patients who received bone marrow grafts from unrelated donors at the same time period. Our aim was mainly the assessment of the incidence of GvHD, but also the outcome of the transplantation in general.

CV

Katerina Kaisari, MD, MSc, is Hematologist. She started working in 2015 at the Bone marrow Transplantation (BMT)Unit at «Aghia Sophia» Children's Hospital,Children's Oncology Unit «Marianna V. Vardinoyannis-ELPIDA», Athens, Greece, where she is still working as Consultant. She is currently the coordinator of bone marrow transplantations for her Dpt. Current practice and research interest involve also all fields of Pediatric Hematology Oncology with focus on several fields of Bone Marrow Tranplantation including infections in immunocompromised children. She is also member in many national and international scientific societies.
She graduated from the Medical School, «National & Kapodistrian University of Athens» and awarded speciality in «Evaggelismos»Hospital. She has also graduated from the School of Health Sciences & Education of «Harokopio» University (Department of Nutrition and Dietetics, Thesis: «Detection of mutations in the LDL receptor gene in patients with familial hypercholesterolemia»). She is currently candidate PhD, «Virus specific T-Cells for the treatment of viral infections in children after allogeneic bone marrow transplantation». A Master Degree has also been obtained from the «National & Kapodistrian University of Athens» – Thrombosis, Hemorrhage and Transfusion medicine (Medical School of Athens, Thesis: «Bleeding Disorders around Menopause»). She is co-author of several publications in all fields of Hematology and in Pediatric Hematology- Oncology / BMT in particular.

Karatasaki Sofia

The success story of volunteer haematopoietic stem cell donation in Greece.
The role of ORAMA ELPIDAS Bone Marrow Donor Center
(Supportive Care)

An overview of volunteer bone marrow donation in Greece, highlighting the contribution of Donor Centers in the increase of registered volunteer Greek donors. Underlining the role of ORAMA ELPIDAS, the largest Greek Donor Center, in enriching the Greek Donor Registry and increasing the number of donations to patients globally. Currently, 10 years after its foundation, ORAMA ELPIDAS has recruited approximately 160,000 donors, more than 360 of whom have proceeded to donate hematopoietic stem cells to patients.

CV

Sofia Karatasaki is a graduate of the School of Biology of the Aristotle University of Thessaloniki, holds an MSc in Translational Medicine (Liverpool University, UK), and an MPhil in B-cell receptor signaling in Chronic Lymphocytic Leukaemia (Liverpool University, UK). Currently, she is working as a Search & Transplant Coordinator, in the Donor Center ORAMA ELPIDAS.

Kattamis Antonis

Cancer Predisposition Syndromes – introduction
(Supportive Care)

Many patients with pediatric cancer may have genetic defects for a cancer predisposition syndrome (CPS). Proper evaluation and guidance for CPS has become an indispensable part of the holistic management of pediatric cancer. A multidisciplinary approach is essential for optimal outcome.

CV

Prof. Antonis Kattamis
Head, Division of Pediatric Hematology-Oncology
First Department of Pediatrics, National and Kapodistrian University of Athens,
'Aghia Sophia' Children's Hospital

SPEECH TOPIC & SHORT BIO

Antonis Kattamis is Professor of Pediatrics – Pediatric Hematology–Oncology at the National and Kapodistrian University of Athens (NKUA). He is the Head of the University Hematology -Oncology and the Thalassemia Units at the "Aghia Sofia" Children's Hospital, Athens, Greece, which are recognized as European Reference Network Centers for Rare Blood Disorders (EuroBloodNet), Pediatric Cancer (PaedCan) and Cancer Predisposition Syndromes (GENTURIS). He has published >170 articles and participated in numerous clinical trials and collaborative research programs, funded by the European Union, NKUA and Pharmaceutical companies.

Kline Cassie | MD, MSCE

Low grade gliomas: how I treat (NF and non-NF)
(CNS Tumors)

While low-grade gliomas have an overall favorable overall survival, the clinical course of patients carrying this diagnosis is commonly affected by significant morbidity. Depending on the affected anatomic region and the therapies needed to treat them, patients can suffer from visual deficits, endocrine issues, neurocognitive injury, and growth problems. The challenge for optimal management of these patients is to balance optimal progression-free and overall survival with preservation of function. In recent years, molecular drivers of these tumors have been identified and targeted therapies subsequently developed against these drivers. Some of these are now in late phase clinical trials. Such targeted options have added to standard surgery, chemotherapy and, less commonly, radiation approaches. In her talk, Dr. Kline will discuss current clinical, molecular and therapeutic considerations in the treatment of pediatric low-grade glioma.

CV

Dr. Kline is a pediatric neuro-oncology attending and Director of Neuro-Oncology Clinical Research at the Children's Hospital of Philadelphia (CHOP). Dr. Kline completed her residency in pediatrics at CHOP followed by a fellowship in pediatric hematology-oncology at the University of California San Francisco (UCSF). While at UCSF, Dr. Kline completed a Master's in Clinical Research and subsequently stayed on as early faculty before returning to CHOP in her current role. Dr. Kline's academic focus is clinical research and early phase trial development for pediatric central nervous system tumors, with a particular focus on diffuse midline gliomas (DMG) and craniopharyngioma. To this end, she currently leads or co-leads several clinical trials dedicated to novel therapies for children and young adults with DMG and craniopharyngioma, bringing together novel drugs, new therapy combinations, and investigational drug delivery systems. In addition to the above work, Dr. Kline serves as the Project Co-Leader and Director of Data Quality and Integration for the Pacific Pediatric Neuro-Oncology Consortium (PNOC), a member of the Children's Brain Tumor Network (CBTN) Scientific Committee and Executive Board, and co-lead of both the CHOP Cancer Center Diversity Committee and PNOC/CBTN DEI working group.

BUILDING BRIDGES IN PEDIATRIC HEMATOLOGY-ONCOLOGY

In memoriam of
Marianna V. Vardinoyannis,
Founder of ELPIDA Association

ΕΛΠΙΔΑ
ΣΥΛΛΟΓΟΣ ΦΙΛΩΝ ΠΑΙΔΙΩΝ ΜΕ ΚΑΡΚΙΝΟ
ELPIDA
ASSOCIATION OF FRIENDS OF CHILDREN WITH CANCER

SPEECH TOPIC & SHORT BIO

Komitopoulou Anna | M.D, PhD, Haematologist

Donor derived Car-T cells for relapses of pediatric CD19 + B-ALL after HSCT (ALL)

Autologous (donor cells derived from recipient) CAR-T cells is a therapy indicated for children and young adult patients (3 to 25 years old), with CD19+ B cell acute lymphoblastic leukemia, who experience relapsed or refractory disease after allogeneic hematopoietic stem cell transpanation.
However, there are patients who either are not eligible for autologous T-lymphocyte collection and CAR-T cell production or patients who experience relapse after autologous CAR-T cell therapy.
For those patients, CAR-T cells derived directly from the donor may be a reliable and effective alternative.

CV

Current position: Consultant Haematologist in Stem Cell Transplant Unit- Centre for Cell and Gene Therapy, Pediatric Oncology Centre "Marianna V.Vardinoyiannis- ELPIDA"- "Aghia Sophia" Children's Hospital, Athens, Greece

Medical degree: Medical School, Democritus University of Thrace, Alexandroupolis, Greece
PhD degree: Medical School, University of Athens and Haemostasis and Thrombosis Unit, Haemophilia Centre, "Aghia Sophia" Children's Hospital, Athens, Greece
Medical training in Internal Medicine: "Sismanogleion" General Hospital, Athens, Greece
Medical training in Hematology: Department of Haematology and Bone Marrow Transplantation Unit, "Evangelismos" General Hospital, Athens, Greece, Department of Laboratory Haemotology, Haematology of Pregnancy and Neonates, "Elena Venizelou" Maternity Hospital, Athens, Greece
Training in Haemostsasis/Thrombosis: Haemostasis and Thrombosis Unit, Haemophilia Centre, "Aghia Sophia" Children's Hospital, Athens, Greece, Clinical Course, Clinic of Internal Medicine, Angiology, Haemostasis and Haemophilia Centre, Vivantes Klinikum im Friedrichschain, Berlin, Germany
Work experience as medical specialist
Consultant haematologist, "Hygeia" Hospital, Athens, Greece (2012–2018).
Consultant haematologist Stem Cell Transplant Unit – Centre for Cell and Gene Therapy, Pediatric Oncology Centre "Marianna V.Vardinoyiannis- ELPIDA"- "Aghia Sophia" Children's Hospital, Athens, Greece (3/2018 until now)
Teaching experience: Presenter, tutorials in haematology/paediatric haematology

Research experience

- Sub-Investigator or Co-Investigator in Phase1/2, 2 and 3 Studies and participation in International or European Studies
- Author or co-author of a considerable number of original articles or review articles
- Presentations in scientific congresses/meetings (6 awards for best presentation)

Other activities

- Participation in JCI accreditation, Hygeia Hospital and FACT-JACIE accreditation, Stem Cell Transplant Unit- Centre for Cell and Gene Therapy, Pediatric Oncology Centre "Marianna V. Vardinoyiannis ELPIDA"- "Aghia Sophia" Children's Hospital
- Reviewer, Editor or Editor in Chief in International Medical Journals
- Member of, EHA, EBMT, SIOPE, Hellenic Society of Haematology, Hellenic Society of Pediatric Hematology Oncology
- President (2021–2022) and Vice-President (2022–2023) of steering committee of Bone Marrow Transplantation and Cellular Therapies of Hellenic Society of Hematology

Lada Elena

Paving the way for probiotic therapy in childhood cancer
(Supportive Care)

The role of microbiome in human health has been a growing area of interest, particularly in cancer. Perturbations to the microbiome have been associated with risk of childhood leukemia, increased toxicities during treatment, alterations in nutritional status, and survival among adults undergoing hematopoietic stem cell transplant. This presentation will summarize the existing data that has evaluated the microbiome in children with cancer as well as provide an overview of clinical trials administering probiotic therapy to children with cancer.

CV

Dr. Elena J. Ladas is the Sid and Helaine Lerner Professor of Global Integrative Medicine in the Division of Pediatric Hematology/Oncology/Stem Cell Transplant at Columbia University Irving Medical Center (CUIMC). Dr. Ladas is a clinical investigator with an expertise in the clinical integration and scientific evaluation of nutrition and complementary/ alternative medicine in pediatric oncology. Dr. Ladas is the principal investigator on a number of multi-institutional studies that evaluate the role of nutrition and integrative therapies, as components of supportive care, during and after treatment for childhood cancer. Dr. Ladas is the founder and director of the International Initiative for Pediatrics and Nutrition (IIPAN) at CUIMC, which aims to enhance nutritional capacity and high-quality research among pediatric cancer units in 34 hospitals located in low- and middle-income countries. In 2019, Dr. Ladas formalized a collaboration with the International Agency for Research on Cancer, World Health Organization (Lyon, France). IIPAN and IARC are leading two multi-national nutrition bio-banking programs in children with cancer including a Southern European initiative evaluating the Mediterranean lifestyle, microbiome, and metabolome in children with cancer.

Suzanne MacFarland

**Cancer Predisposition in Pediatrics:
considerations for testing and screening in children
(Supportive Care)**

Molecular testing has been incorporated into diagnosis, risk stratification, and treatment decisions in pediatric oncology, and often leads to diagnosis of underlying cancer predisposition. Alternately, patients may be identified based on family history, clinical features, or tumor type. However, there are specific ethical dilemmas and challenges that arise in testing children and diagnosing a cancer predisposition screening. Consideration of patient autonomy in testing and result disclosure, benefit and burden of screening, testing of family members, and interpretation of results all require specific considerations in pediatrics.

CV

Personal Statement:

I am a physician scientist and attending physician at the Children's Hospital of Philadelphia, with a focus on pediatric cancer predisposition syndromes. I have a particular clinical and research interest in both pediatric polyposis syndromes and Li-Fraumeni Syndrome. I initiated a study to uncover novel genomic drivers in Juvenile Polyposis Syndrome (JPS) in patients without a mutation in BMPR1A or SMAD4, funded both by philanthropic and institutional sources as well as the Department of Defense. I led a multi-institutional collaboration demonstrating a distinct clinical phenotype in these patients with mutation-negative JPS, which has been incorporated into national JPS guidelines. I have also worked with the pediatric and adult data available to further define colorectal cancer risk in other cancer predisposition syndromes, including Li-Fraumeni syndrome. More recently, I have also been funded to study educational and support tools for patients undergoing genetic testing early in cancer diagnosis, and after diagnosis of a cancer predisposition syndrome. Through my participation in these projects and in associated consortia –including the Consortium for Childhood Cancer Predisposition (C3P) and the Early Detection in Syndromic Neoplasms (EDISYN) Consortium, I have gained research expertise in genomics, human subjects research, and clinical trials that will facilitate my ongoing work in this field.

SPEECH TOPIC & SHORT BIO

Makrythanasis Periklis

Genetic predisposition for Wilms

Wilms tumor is the most common renal malignancy in children <15 years old, accounting for approximately 95 percent of all cases, two-thirds of which are diagnosed before five years of age and 95 percent before 10 years of age. The worldwide incidence of Wilms tumor, while varying by region and population, is generally estimated to be about 8 to 10 cases per million children under the age of 15 years. Wilms tumor appears to be caused by abnormal renal development and the presentation will focus on the known genes and related genetic diseases and syndromes that are known to be associated with the development of the disease.

CV

Periklis Makrythanasis, MD, PhD, PD, is a Medical Geneticist and currently holds the position of Assistant Professor of Medical Genetics in the Laboratory of Medical Genetics, of the Medical School of Athens (National and Kapodistrian University of Athens). He is member of the National Committee for Rare Diseases, and coordinates the committee about the specialty of Medical Genetics in Greece. His work is divided between the clinical care of patients with rare diseases and research that is mainly focused on the diagnosis of patients with rare diseases and the discovery of novel genes responsible for them.

Morgenstern Daniel

Current and future strategies for relapse / refractory high-risk neuroblastoma (Solid Tumors – 2)

This presentation will cover recent developments in treatment options for relapse/refractory high-risk neuroblastoma, review potential future therapeutic targets and provide an overview of upcoming trials.

CV

Daniel Morgenstern is a Staff Oncologist at Hospital for Sick Children, Toronto and Associate Professor at the University of Toronto. He originally trained and worked in the UK, primarily at Great Ormond Street Hospital in London where he was clinical lead for the neuroblastoma and autograft programs, and an active member of SIOPEN. Dr Morgenstern moved to SickKids, Toronto in 2016 as Director of the New Agent and Innovative Therapy (NAIT) and Therapeutic mIBG Programs, and co-lead of the neuroblastoma service. He is also Medical Director of the Oncology/BMT Clinical Trials Support Unit. Dr Morgenstern's clinical activities are focussed on neuroblastoma and solid tumour patients participating in early phase clinical trials. His research interests are in early phase trials and, in particular, the use of immune checkpoint inhibitors in paediatric cancers and the development of precision medicine approaches for paediatric solid tumours.

Nanis Dimitris

Psychological care after the end of therapy
(Supportive Care)

The survival rate of childhood cancer is constantly improving. However, the psychosocial long-term consequences are becoming evident for the survivors and their families, underlining the necessity for continuous care after the completion of treatment. Nevertheless, even if the need for medical follow-up programs is widely recognized, psychosocial aftercare is still in its infancy.
Research findings indicate that the children surviving cancer are seriously affected by the cancer experience. Different types of interventions need to be developed based on the nature of the problems and the level of adjustment of every survivor. The psychosocial follow-up programs contribute to the reduction of late effects and the improved quality of life following end of treatment.
The challenge for Pediatric Psycho-oncology is the development and the clinical application of appropriate psychosocial follow-up programs for children and adolescents cured from cancer, in order to enhance their well-being and facilitate their reintegration into the educational system and the community.

CV

My name is Dimitrios Nanis and I was born in Germany.
I obtained my Social Work Degree from University of Patras in 09/1995
In 2004, I completed my Systemic Psychotherapy education.
In 2014, I obtained my MSc Degree, from National and Kapodistrian University of Athens, Medical School Department of Epidemiology.
From 2021, I am a PhD Candidate in Medical School, National and Kapodistrian University of Athens.
I have been working in "Elpida" Association of friends of children with cancer since 09/1999, the last 10 years as Assistant Manager in the Guest House and Head of Psychosocial Support Services.
During these years in the field of Pediatric Oncology, I have actively participated in multiple conferences.
I am a member of several professional Societies, like IPOS, Greek social workers etc.

SPEECH TOPIC & SHORT BIO

Oikonomopoulou Christina

Emerging molecular/cytogenetic markers at cell therapies (ALL)

Allogeneic hematopoietic stem cell transplantation (HSCT) is an established potentially curative therapy for high – risk pediatric Acute Lymphoblastic Leukemia (ALL). CD19 Chimeric Antigen Receptor (CAR) T-cell therapy has been shown to be effective at achieving durable remissions for children with B-ALL. The goal of this presentation is to evaluate the potential emerging role of molecular and cytogenetic markers for the outcome of HSCT and CAR T cell therapies in childhood ALL and moreover to access if the already recognized prognostic significance of specific markers at diagnosis is also applicable to outcome of children with ALL after cell therapies.

CV

Christina Oikonomopoulou was born and grew up in Athens. She graduated from Medical School of Athens in 2002 and obtained her PhD in 2009, working on Myelodysplastic Syndromes. She completed her Medical Training in Hematology Unit of Attikon University Hospital in 2013 and obtained the title of Hematologist in March 2014. Since then, she worked first as a part-time University Fellow at Hematology Unit of Attikon and concurrently, at the Hematology Clinic of Laikon Hospital in Athens (till Apr 2016). From April 2016 until today, she has been engaged in BMT in children in BMT Unit of Aghia Sophia Children's Hospital in Athens, at first as a University Fellow and from Dec 2018 till today, as a Consultant of Hematology. She has an active participation in Greek and European/international Congresses in Hematology and Bone Marrow Transplantation, with 54 abstracts in Greek Congresses and 31 abstracts in International Congresses. She has also been involved in the preparation of 24 manuscripts that have been published in international medical journals. Her main research interests are focused on bone marrow transplantation, cellular therapies, and gene therapy.

Papadakis Vassilios

Neuroblastoma – Novel Approaches / developments (SIOPEN)
(Solid Tumors – 2)

This talk will focus on the lessons learned for the major SIOPEN HR 1 study, the research questions of the HR 2 study and the current amendments. The progress of the LINES protocol will be reviewed too. For relapse/ refractory NBL disease the concepts and results of the MiniVan study, the BEACON studies, the RIST and the VERITAS protocols will be reviewed. Further developments on the immuno-chemotherapy and evolving concepts on the use of liquid biopsies, as well as novel directions in the treatment of neuroblastoma in Europe will also be presented.

CV

Vassilios Papadakis MD PhD
Director of the Department of Pediatric Hematology- Oncology
Marianna V. Vardinyiannis- ELPIDA
"Agia Sofia" Children's Hospital, Athens Greece

Pediatrics – Hematology – Pediatric Hematology Oncology

Dr Vassilios Papadakis graduated from the Medical School of the University of Athens with summa cum laude and continued with Residency in Pediatrics at St Luke's / Roosevelt Medical Center of the Columbia University of Physicians and Surgeons (New York City, USA 1987) and Fellowship in Pediatric Hematology- Oncology at Memorial Sloan-Kettering Cancer Center and NYH-Cornell Medical Center (1990). Research activities involved the pathophysiology of bone marrow engraftment and failure following BMT, CNS tumor megatherapy/ transplantation and late effects of cancer treatment, all with relevant publications.
Dr Vassilios Papadakis is Board Certified in 1. Pediatrics and in 2. Pediatric Hematology Oncology in the USA and holds the Specialty Title of 3. Pediatrics and 4. Hematology in Greece.
He has been working at the Department of Pediatric Hematology – Oncology at Aghia Sophia Children's Hospital in Athens, Greece since 1997, at the Director tier since 2011, Head of the Department since 2023.
A PhD Degree was defended successfully at the University of Crete (Long-term outcome of growth and gonadal function in children treated for Hodgkin's Lymphoma).
Current research activities involve Neuroblastoma, Leukemias, Lymphomas and Histiocytic Syndromes together with the Long-Term Outcome of children treated for malignancies. Clinical practice involves the full spectrum of Pediatric Hematology – Oncology.
Dr. Papadakis is National Principal Investigator of the LCH-IV Protocol in Greece (Langerhans Cell Histiocytosis), also leading the Histiocytoses Chapter of the National Society. He serves in the Educational Committee

of the Histiocyte Society (2019-present, currently Chair) and also the Board of ECHO (European Consirtium for Histiocytosis, treasurer).
He has also been founding member of SIOPEN (Neuroblastoma Europe) and has served at the SIOPEN Executive Committee (2006–2000, 2012- 2016, 10/2020- current, Treasurer), he is PI for SIOPEN Neuroblastoma studies and National Lead for Neuroblastoma. He also enjoys being a member of the Board (Medical Doctor) of the Make-A Wish Foundation Greece.
Recent funding is the MonaLisa project (HORIZON EU, 2024): A SIOPEN pragmatic clinical trial to MOnitor NeuroblastomA relapse with Liquid biopsy Sensitive Analysis, 2023–2028, being Work-package leader for: Patient reported outcomes, quality of life and patient advocacy aspects.

Roka Kleoniki

GENTURIS guidelines for NF: "gnous pratte"
(CNS Tumors)

The phrase «γνους πράττε» (gnous pratte) is attributed to Pittacus of Mytilene, one of the Seven Wise Men, philosophers of the 7–6th century BCE, and could be translated as "to act with awareness, to act knowing". GENTURIS Guidelines for NF1 is an effort of the European Reference Network for Genetic Tumor Risk Syndromes, to improve tumor surveillance and quality of care for NF1 all over Europe by providing evidence-based information. This information as well as the main questions that remain unanswered alongside the challenges in the era of targeted therapy for NF1 will be the main objectives of this lecture.

CV

Kleoniki Roka is a Paediatrician, MD, PhD, and a Senior Consultant in the University Division of Pediatric Hematology-Oncology (UPOHemU), First Dpt of Pediatrics, National and Kapodistrian University of Athens. Since 2009, she has been working with pediatric hematology-oncology patients and was trained in Pediatric Intensive Care, specialising in pediatric hematology-oncology critically ill patients for three years. In 2019 she attended the International Learner Program (Neurooncology Observership) at SickKids, Toronto, Canada.
Her main areas of focus include neurooncology, neurocutaneous disorders- mainly neurofibromatosis type 1, and cancer predisposition syndromes. She is one of the basic members of the Neurocutaneous Clinic established in 2016, a member of the extended team of the Thematic Group 1 for Neurofibromatosis, and a member of the core team of Task Force 6 for collaboration, communication, dissemination, and patient empowerment in the European Reference Network GENTURIS. Finally, she is a SIOPe LGG Working Group member and the main author of the SIOPe European Standard Clinical Practice Recommendations for Low-Grade Gliomas.

Saloustros Emmanouil

Special needs of the adolescent patient (AYA)

In his presentation Dr Saloustros will address the characteristics of cancer in adolescents and young adults. In specific the epidemiology and most common cancer types diagnosed in AYA, the unique characteristics of the disease, as well as the management and psychosocial issues that should be addressed in order to serve this population in the best possible way.

CV

Affiliations: Faculty of Medicine, Division of Oncology, School of Health Sciences, University of Thessaly.

Emmanouil Saloustros MD, DSc, obtained his Medical Degree (MD) from the University of Thessaly in 2000 and completed his residency in Internal Medicine and fellowship in medical oncology at the University Hospital of Heraklion (2010).
He conducted post-graduate research at the Section on Endocrinology & Genetics of the Eunice Kennedy Shriver National Institutes of Child Health and Human Development at the National Institutes of Health (NIH), focusing on heritable disorders that predispose to cancer, mouse models of human tumours and related issues.
In 2013 he obtained his doctoral degree in cancer biology from the University of Crete School of Medicine.
For six years (2012–2018) Dr Saloustros has served as consultant of medical oncology at the General hospital of Heraklion 'Venizelio' and established the hereditary cancer clinic at the University hospital of Heraklion, both in Crete, Greece. In June 2018 Dr Saloustros moved to Larissa, to join the Faculty of Medicine of the University of Thessaly.
Dr Saloustros research is primarily focused on breast cancer risk and management, the BRCA1/2 associated breast and ovarian cancers, and the hereditary syndromes that predispose to colorectal cancer. In parallel he studies the genetics of non-BRCA1/2 associated breast cancer in collaboration with the breast cancer association consortium (BCAC).
He has served the ESMO/SIOPE WG on cancer in AYA as chair for four years and involved in several projects and educational activities in cancer topics specific to this population.

SPEECH TOPIC & SHORT BIO

Seif Alix | MD

The role of alloBMT in first line ALL treatment (ALL)

Indications for consolidative hematopoietic stem cell transplantation (HSCT) for high-risk pediatric acute lymphoblastic leukemia (ALL) have evolved with the advent of highly sensitive disease detection and development of targeted small molecule inhibitors and immunotherapies/ This talk will provide an overview of when to consider HSCT for ALL in first remission, highlighting patients with infant ALL, Philadelphia chromosome-positive ALL, and those with persistence of measurable residual disease.

CV

Personal Statement:

I am a pediatric oncologist who specializes in leukemia and hematopoietic stem cell transplantation (HSCT). My current research focuses on developing and implementing patient-centered interventions to improve outcomes, quality of life, and equity for pediatric patients with hematologic malignancies. I have collaborated with the Children's Hospital of Philadelphia (CHOP) Cancer/Infectious Diseases Epidemiology working group since its inception in 2009. Our group has assembled large cohorts of children with ALL and AML using administrative datasets merged with clinical trial data from the Children's Oncology Group (COG). In my role as the leader of CHOP's "Graft-versus-Leukemia" group, I have been responsible for collaboratively developing and implementing multiple new clinical standards for children undergoing HSCT to treat leukemia.
I provide expert consultations on all patients with suspected EBV-related tumors after solid organ transplantation (SOT). We developed a multi-disciplinary team to develop clinical standards for monitoring EBV prospectively in the post-SOT setting, aiming to identify risk factors for development of post-transplant lymphoproliferative disorders (PTLD) and EBV-associated smooth muscle tumors (SMT), to detect incident cases early in the clinical course, and to develop effective prevention and treatment strategies.

Servitzoglou Marina

Psychosocial care for children and adolescents with cancer
(Supportive Care)

The impact of cancer on children's and families' quality of life is adequately recognized. There are several evidence-based Guidelines for Psychosocial Care for Children with Cancer, which describe not only the stressful situations which make more vulnerable the young patients, but also those who are more susceptible to psychological distress due to subjective reasons.
The provision of comprehensive psychosocial care throughout the course of illness could reduce the burden of cancer and required treatment. The appropriate interventions to mitigate the impact of cancer and related treatment have been well recognized, but the provided Psychosocial care can still significantly vary across Oncology Centers. The consistent implication of Psychosocial Standards remains challenging and requires the allocation of all necessary resources to ensure the best possible care for children and adolescents with cancer.

CV

Medical Degree from University of Patras in 09/1994 and PhD in Psychosocial Oncology from University of Athens in 09/2004.
Specialization in Pediatrics at the Children's Hospital "P. & A. Kyriakou" from 01/2000 to 01/2004 and Subspecialization in Pediatric Hematology/Oncology, in United Kingdom and France from 07/2004 to 04/2008.
PostGraduate Diploma in Pediatric Palliative Care from Cardiff University in 07/2007 and Diplôme InterUniversitaire d' Oncologie Pédiatrique from Université Paris-Sud 11 in 10/2009.
Pediatric Oncology NHS Consultant at Children's Hospital "P. & A. Kyriakou" since 05/2008.
Participation in the National Ethics Committee of the National Organization for Medicines since 2013 and Member of Greek HTA since 2021.
Founding member of Greek Society of Pediatric Palliative Care and member of several professional Societies.

SPEECH TOPIC & SHORT BIO

Stutterheim Janine

Infant acute lymphoblastic leukemia – the INTERFANT experience

Acute lymphoblastic leukemia in infants, is a rare and aggressive type of leukemia. Rearrangements of the KMT2A gene, formerly known as MLL gene, occur in 75 % of infants with ALL, and is associated with a poor outcome. In the late nineties the Interfant group was established that launched an international collaborative protocol that added low and high dose cytarabine to an ALL backbone. This was based on in vitro resistance to common ALL drugs such as corticosteroids and asparaginase and increased sensitivity to cytarabine. Although this approach increased the outcome, the 6-year EFS for KMT2A-rearranged infant ALL in Interfant99 and Interfant06 did not reach 50%. In the last decades also several targeted drugs (eg Azacitidine, FLT-3 inhibitors, HDAC inhibitors) have been investigated in clinical trials. Of those drugs, only blinatumomab seems to be of great benefit. In future, the role of BCL2-inhibitors and menin-inhibitors will be answered.

CV

Janine Stutterheim is a pediatric oncologist working in the Princess Máxima Center in the Netherlands. She is specialized in pediatric acute lymphoblastic leukemia and coordinating principal investigator of the current Interfant-21 trial. She is also one of the principal investigators for the phase 1 trial investigating the menin-inhibitor, ziftomenib, in patients with relapse and refractory acute leukemia with specific aberrations, such as KMT2A-rearrangements. One of her goals is to in bring experimental drugs, such an menin-inhibitors, to front-line treatment in infant ALL.

BUILDING BRIDGES IN PEDIATRIC HEMATOLOGY-ONCOLOGY

In memoriam of
Marianna V. Vardinoyannis,
Founder of ELPIDA Association

ΕΛΠΙΔΑ
ΣΥΛΛΟΓΟΣ ΦΙΛΩΝ ΠΑΙΔΙΩΝ ΜΕ ΚΑΡΚΙΝΟ
ELPIDA
ASSOCIATION OF FRIENDS OF CHILDREN WITH CANCER

SPEECH TOPIC & SHORT BIO

Tasian Sarah

Emerging therapies for pediatric AML

Despite risk-adapted therapy for children with AML based upon underlying leukemia-associated genetics and end-induction measurable residual disease response, relapse and primary chemotherapy-refractory disease remain a major clinical issue. Successful development of targeted inhibitor and immunotherapeutic approaches for pediatric AML remain an unmet medical need. This presentation will focus upon emerging innovative targeted therapeutic approaches under early-phase clinical investigation for children with specific high-risk subtypes of relapsed/refractory AML.

CV

Personal Statement:

My research program at CHOP focuses on identification of targeted therapeutic strategies **for childhood leukemias via (1) characterization of critical intracellular biology and preclinical testing of kinase and other small molecule inhibitors in genetic subtypes of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), (2) preclinical testing of chimeric antigen receptor (CAR) T cell immunotherapies for high-risk AML and ALL, and (3) early-phase clinical testing of** molecularly-targeted **therapies for children with leukemia** through the Children's Oncology Group (COG) and other consortia. I serve as the Chief of the Hematologic Malignancies Program at CHOP and hold the Joshua Kahan Endowed Chair in Pediatric Leukemia Research. I am an executive member of the COG ALL Committee, the COG Myeloid Diseases Committee (Vice Chair of Relapse), the COG Developmental Therapeutics Committee (Vice Chair of Biology for Hematologic Malignancies), and the Clinical Trials Leader of the Leukemia & Lymphoma Society PedAL/EuPAL consortium. I also chair the COG AALL1521 clinical trial (ruxolitinib/chemotherapy for children with Ph-like ALL), am vice-chair of the COG AAML2131 clinical trial (dasatinib/chemotherapy vs dasatinib/chemotherapy/blinatumomab for ABL class Ph-like and Ph+ ALL), and co-lead immunotherapy trials for children with relapsed AML (vice-chair of PEPN1812 flotetuzumab phase 1, CD33CART phase 1/2).

SPEECH TOPIC & SHORT BIO

Van den Heuvel – Eibrink Marry

CV

MD, PhD Professor Translational Pediatric Oncology Pediatric Oncologist, and PI. Senior Consultant pediatric oncology and hematology Erasmus MC-Sophia Children's Hospital 1997-2014. Working Group leader at the 'Erasmus MC Postgraduate Molecular Medicine School' which is recognized by the Dutch Royal Academy of Science and Arts, 2009–2015.
Previous chair of the international EWOG-MDS foundation (2007–2016). Chair of the national core group member Dutch Late effects group, and co-PI of the DCOG LATER study (2007–2020). One of the pioneers, since 2015, of the Princess Máxima Center for Pediatric Oncology, where she has established, apart from research regarding the identification of (genetic) determinants of direct and late childhood cancer related toxicity, the national centralized care and translational research, Childhood Comprehensive Cancer program for all Dutch children with renal tumors. Leading the international SIOP-RTSG office trial management team (launched in >25 countries) for the UMBRELLA study, since 2018. Chair of the SIOP-RTSG (2022 onwards), and co-chair of the SIOP-RTSG & COG-RTG consortium (HARMONICA). Professor Translational Pediatric Oncology at the University of Utrecht since 2016. Group leader of a research group of 25 PhD & Post-docs, in the Princess Máxima Center for Pediatric Oncology in Utrecht, Supervisor of > 50 PhD projects (of which >30 already successfully defended).

Her research is dedicated to translational research in pediatric oncology, with a special focus on renal tumors and the (genetic) variation of early and late toxicity of childhood cancer.

Witt Olaf

Pediatric Precision Oncology in INFORM: lessons learned and future developments (Advances in diagnosis and treatment)

The INFORM pediatric precision oncology program, spanning 100 centers across 12 countries, has enrolled over 3000 relapsed and high-risk pediatric cancer cases. It offers comprehensive molecular testing, target identification, and tumor classification, supported by weekly molecular tumor boards. For patients with high-level targets, molecular matching therapy doubled median progression-free survival (PFS) and overall survival (OS). The program also detects cancer predisposition syndromes. This success led to German health insurances covering the cost of INFORM molecular diagnostics. However, many cancers lack clinically relevant molecular alterations detectable by current technologies. To address this, INFORM integrates new technologies like drug sensitivity profiling and proteomics while refining bioinformatic algorithms. INFORM2 and 3 will focus on enrolling patients with novel predictive molecular biomarkers for interventional trials.

CV

Prof. Olaf Witt, MD is the Director of the Translational Program of the Hopp Children's Cancer Center Heidelberg (KiTZ), Division Head of the CCU Pediatric Oncology at the German Cancer Research Center (DKFZ), and the Section Head of the Phase I/II Clinical Trial Unit and Brain Tumors Department of Pediatric Oncology, Hematology, Immunology and Pulmonology at the University Hospital Heidelberg. He studied medicine at the Universities of Münster, Hamburg and Michigan, USA and is specialized in the field of pediatrics, neonatal medicine and pediatric oncology and hematology. Olaf Witt started his scientific career at the University of Göttingen Medical School and was appointed to his current position as a full professor for pediatric oncology in 2005.

Professor Witt's major interest is the identification of biomarkers for response prediction in precision medicine as well as in developing rationale treatment combination strategies to overcome resistance in pediatric oncology. Since 2015, Olaf Witt is coordinating the (inter)national precision program in pediatric oncology termed "INFORM" (INdividualized Therapy FOr Relapsed Malignancies in Childhood) and based on this is developing innovative phase I/II biomarker driven combination basket trials series termed "INFORM2". He is coordinating investigator of the pan-European low grade glioma phase III trial (LOGGIC Europe Trial) study group and elected board member of the German Society of Pediatric Oncology and Hematology (GPOH). He is author of more than 200 publications.

SPEECH TOPIC & SHORT BIO

Zaoutis Theoklis

ID Prophylaxis in pediatric Oncology
(Supportive Care)

In his talk, he will describe patients at risk for infections and outline infection prophylaxis since pediatric oncology patients are at risk due to myelosuppression, immunity alteration, disruption of integumentary barrier integrity, changes in colonizing microflora, and undernourishment and outline the routine infection prophylaxis for at risk patients based upon primary oncologic diagnosis.

CV

Theoklis Zaoutis, MD, PHD is currently Professor of Pediatrics at the School of Medicine of the National Kapodistrian University of Athens in the Second Department of Pediatrics based in the P and A Kyriakou Children's Hospital. He served as director of Greek CD during the COVID-19 pandemic.. He is Emeritus Professor of Pediatrics at the Perelman School of Medicine, University of Pennsylvania (PENN)/Division of Infectious Diseases, Children's Hospital of Philadelphia (CHOP). He is an internationally recognized infectious disease expert, epidemiologist, and pediatrician, with over 360 articles in scientific journals and has been awarded multiple distinctions, including the Healthcare Epidemiology Pediatric Investigator Award in 2009 and the Distinguished Service Award by the Pediatric Infectious Diseases Society in 2015. His research and clinical care has focused on infections in the immunocompromised child. He launched and co-directed the International Pediatric Fungal Networ.

Zwaan Michel

Drug Development in Pediatric Oncology
(Advances in diagnosis and treatment)

Dr. Zwaan's presentation will mainly focus on drug development for pediatric cancers, and provide examples of the changing landscape such as pediatric development occurring very early after the adult recommended dose is established, and incorporating new agents in front-line treatment, for example with the menin inhibitors. Moreover, the role of Accelerate will be addressed and the potential benefits of the new EU-pharmaceutical legislation. Moreover we will touch upon the role of academic intent-to-file clinical trials.

CV

Prof dr. Michel Zwaan was registered as a pediatric oncologist in 1999 after training at the VU Medical Center Amsterdam. He obtained his PhD on 'Drug Resistance in Pediatric AML', and defended it cum laude in 2003. In 2005 he moved to Erasmus MC-Sophia Children's Hospital, Rotterdam, and focused on translational research into myeloid malignancies and early drug development. In 2014 he was appointed as 'professor in Pediatric Oncology with emphasis on drug development' and he led the department of Pediatric Oncology/Hematology in Rotterdam from 2014–2018, after which he started working at the Princess Máxima Center for Pediatric Oncology in Utrecht. There he is appointed as a workgroup leader for Drug Development/Experimental Therapeutics and Medical Chair of the Trial and Data Center. He is a member of the Executive Board of ITCC (www.itcc-consortium.org) and chairs the Hematology Committee of ITCC. He is an international coordinating Principal Investigator of several studies conducted in the regulatory context of a Pediatric Investigational Plan (intent to file), with Erasmus MC or Princess Máxima acting as international coordinating sponsor. Recently, bosutinib (Sept 2023) and inotuzumab ozogamicin (March 2024) were FDA approved for use in children based on these studies. He chairs the Ethics Committee of the METC Utrecht (MedNec) and he also chairs the NVMETC (Dutch Association for Medical Ethical Review Committees).

Sponsored by

ΕΛΠΙΔΑ
ΣΥΛΛΟΓΟΣ ΦΙΛΩΝ ΠΑΙΔΙΩΝ ΜΕ ΚΑΡΚΙΝΟ
ELPIDA
ASSOCIATION OF FRIENDS
OF CHILDREN WITH CANCER

Organized by

Hellenic Society of Pediatric Hematology - Oncology

European Reference Network
for rare or low prevalence complex diseases

Under the auspices of

MINISTRY OF HEALTH
AND SOCIAL SOLIDARITY

Scientific Committee

Dimitris Doganis
Evgenios Goussetis
Antonis Kattamis
Vassilios Papadakis

Event Venue

NJV Athens Plaza Hotel,
Athens, Greece

https://www.njvathensplaza.gr

PCO

PROFILGROUP®
COMMUNICATION SERVICES

Congress Organizationnal
and Secreterial Services

T: +30 2310 676 022 - 4 | +30 2130 900 684

e-mail: secretary@profilgroup.gr
https://congress.profilgroup.gr